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Abstract: The management of hepatocellular carcinoma (HCC) remains challenging due to late 
presentation and the presence of accompanying liver dysfunction. As such, most patients are not eligible for 
curative resection and liver transplant. Management in this scenario depends on a number of factors including 
hepatic function, tumor burden, patency of hepatic vasculature and patients’ functional status. Based on 
these, patients can be offered catheter based intra-arterial therapy for intermediate stage disease and in more 
advanced disease, sorafenib. Given recent data, regorafenib is now an option following failure of sorafenib. 
Catheter directed intra-arterial therapy takes advantage of tumor hypervascularity and the unique dual blood 
supply of the liver, as hepatic tumors receive arterial perfusion via the hepatic artery while the rest of the liver 
is supplied by the portal vein. This allows selective embolization and delivery of chemotherapeutic agents to 
the tumor. Compared to best supportive care, intra-arterial therapy offers a survival benefit in intermediate 
stage HCC and is the recommended approach for treatment. None of the catheter based approaches; 
including bland embolization, conventional trans-arterial chemoembolization (cTACE), drug eluting bead 
trans-arterial chemoembolization (DEB-TACE) or trans-arterial radioembolization (TARE) offers a clear 
advantage over the other, although DEB-TACE may be characterized by less systemic toxicity. All of these 
approaches are contraindicated in patients with portal vein thrombosis (PVT). On the other hand, intra-
arterial, radio embolization, with Yttrium-90 (Y90) can be offered to patients with PVT. The place of this 
modality in management of HCC is still being investigated. The role of sorafenib in advanced HCC is not 
in doubt, as until recently, it was the only systemic therapy approved for the management in this setting. 
This is despite multiple trials evaluating other agents. The addition of sorafenib to catheter-based therapy 
in intermediate stage disease has also failed to show any benefit. The modest survival benefit with sorafenib 
and the failure of other targeted agents suggest that it is important to look beyond inhibition of angiogenesis 
in advanced HCC. Identification of key drivers and mediators of HCC remains paramount for successful 
drug development. In line with this, it is refreshing that the excitement that has followed developments 
in cancer immunotherapy is finding its way to HCC with early trials of anti-PD1 monoclonal antibodies 
showing sufficient activity that phase III trials are now ongoing for Pembrolizumab and Nivolumab in 
advanced HCC. Future drug development efforts will focus on defining the feasibility of combining different 
treatment approaches targeting multiple important modulators of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the most common 
primary liver malignancy, accounting for 90% of the 
primary liver cancers in the United States (1). Hepatic 
fibrosis and cirrhosis are the most common precursors to 
the development of HCC. HCC is closely associated with 
chronic hepatitis C and hepatitis B infections. Hepatitis C is 
more common in the United States, affecting over 3 million 
people; however, worldwide Hepatitis B is a more common 
infection. In developed countries, alcohol induced liver 
disease is recognized as a leading cause of HCC. Historically 
HCC had a very poor prognosis, which was in part due to 
advanced stage of disease at diagnosis. With implementation 
of screening programs for at risk individuals, more early stage 
disease was found and outcomes improved with survival rates 
doubling between 1992 and 2004 (1).
The definitive therapies for HCC remain surgical 
resection, ablation or liver transplantation (2); however, 
most patients with HCC are ineligible for these therapies 
due either to disease burden (for transplant and ablation) 
or severity of liver disease (for surgical resection). Multiple 
classification schemes are available to stratify patients with 
preserved hepatic function or poor hepatic function in an 
effort to determine which therapies they can undergo. The 
Barcelona Clinic Liver Cancer Staging (BCLC) system 
is the most widely used and takes into account hepatic 
function, extent of tumor involvement, and performance 
status (3). The BCLC system classifies HCC into five stages 
based on tumor burden, Child-Pugh score, and Eastern 
Cooperative Oncology Group (ECOG) performance 
status (4). Surgical resection is considered in patients 
with preserved hepatic function, normal bilirubin, and 
no portal hypertension (BCLC stage 0). If patients are 
not candidates for resection they may be considered for 
liver transplantation or percutaneous ablative therapies if 
they have a solitary tumor less than 5 cm or three tumors, 
each less than 3 cm (BCLC stage 0 and A). Percutaneous 
therapies such as thermal ablation (cryotherapy, microwave 
ablation, and radiofrequency ablation) or chemical ablation 
can be used as an alternative to surgery (BCLC stage A) (5). 
The remaining patients may be considered for transarterial 
therapies (5) Sorafenib, a multikinase inhibitor is the only 
systemic therapy that has shown a survival benefit for 
patients with HCC (6).
In this article, we will discuss the range of treatments, both 
locoregional and systemic, that is available to treat HCC that 
is not amenable to curative therapy (BCLC B and C). For the 
most part the goal of these treatments is prolongation of life 
and palliation of symptoms rather than cure.
Loco-regional therapy for HCC
There are multiple transarterial therapies available 
based on the tumor size and characteristics as well as 
the patient’s clinical status. These therapies include 
transarterial embolization (TAE), conventional transarterial 
chemoembolization (cTACE), drug eluting bead (DEB) 
transarterial chemoembolization (DEB-TACE), and 
transarterial radioembolization (TARE). The rationale for 
catheter directed local regional therapies in the treatment 
of HCC is predicated on the fact that there is a mismatch 
between blood supply to normal hepatic parenchyma and 
HCC lesions. Normal liver parenchyma receives ¾ of 
its blood supply from the portal vein with the remaining 
¼ arriving via the hepatic artery. In contrast, advanced 
HCC derives the bulk of its blood supply from the hepatic 
artery (7). cTACE and DEB-TACE take advantage of that 
difference in blood supply, allowing for greater delivery 
of embolic agent to the tumor while minimizing insult to 
normal hepatocytes supplied by the same hepatic artery (3).
Transarterial therapy not only provides a survival benefit 
(8-11), in select cases therapies can be used to downstage a 
patient’s tumor burden. The goal of tumor reduction is to 
place the patient back within Milan/UCSF Criteria so they 
may undergo liver transplantation, ultimately offering them 
a chance at a curative therapy. cTACE and DEB-TACE 
are contraindicated in patients with advanced cirrhosis 
(Child-Pugh C) and poor functional status, while tumor 
within the main portal vein, biliary obstruction and hepatic 
encephalopathy are considered relative contraindications.
Embolic therapies in the HCC treatment algorithm
While several staging systems and treatment algorithms 
exist for HCC (5,12), the most widely reported and 
accepted in the literature is the Barcelona Clinic Liver 
Cancer Staging Classification and Treatment Algorithm 
(BCLC) (13). Patients classified as intermediate stage B 
demonstrate multinodular disease outside of transplantable 
criteria with good performance status. These patients are 
typically considered for transarterial treatment options, the 
most common form being TACE. 
TAE
TAE involves the endovascular occlusion of arteries 
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supplying a targeted tumor. TAE has been performed for 
over three decades in the treatment of HCC (14). This form 
of embolization is typically completed with gelatin sponge 
particles, spherical embolic agents or PVA particles alone, 
and is often referred to as “bland” embolization. While 
specific techniques and materials are quite variable, the 
basic goal is induced cell death by severe hypoxia achieved 
via occlusion vascular supplies to the tumor. 
Patient selection 
TAE may be considered in BCLC class B patients and 
is limited in patients with class C disease. While TACE 
carries a 1A recommendation for stage B disease (15), some 
institutions rely on bland embolization due to the overall 
cost versus TACE as well as conflicting studies comparing 
their efficacy (14,16-18). Age has not been demonstrated as a 
factor that impacts outcome with TAE (19). Importantly, no 
definitive exclusion criteria based on laboratory values exists 
for TAE treatment; however, advanced cirrhosis, elevated 
total bilirubin >4 mg/dL, serum creatinine >2 mg/dL, 
portal vein involvement and hepatic encephalopathy are 
considered relative contraindications. 
Technique and considerations
Arterial access is obtained and catheter and microcatheter 
combinations are used to select the hepatic arterial branches 
supplying a tumor. From that location, embolic agents are 
infused until stasis of flow is seen in the selected artery. The 
goal of catheter placement is to ensure complete vascular 
coverage of the tumor with sparing of as much normal 
parenchyma as possible, limiting the amount of normal 
tissue ischemia and post embolization syndrome. Embolic 
agents selection and composition varies, but small embolic 
material sizes generally range from 40–300 μm (15). One 
important consideration in catheter directed embolotherapy 
involves intra-tumoral arterial-venous shunts, which may 
result in inadvertent pulmonary arterial embolization if 
particle size is too small. 
Post embolization syndrome may be experienced in 
patients and is typically worse in those requiring larger 
territorial embolization. This is usually self-limited and may 
present with abdominal pain, nausea, vomiting, ileus, fatigue 
and/or fever within the first 72 hours post-embolization (20). 
For that reason, patients treated with both TAE and TACE 
are commonly admitted overnight to the hospital for pain 
control prior to discharge, usually the following morning. 
Post-procedure imaging and laboratory assessment are 
typically completed 4–6 weeks after treatment to assess 
response. Treatment may require multiple sessions if 
additional vascularity or progression of disease is noted on 
post procedure imaging.
Outcomes
Studies have demonstrated survival benefit with TACE 
relative to supportive care. No such comparative data 
exist for TAE; some studies have demonstrated inferior 
survival response with TAE (16). While meta-analysis data 
suggesting non-inferiority of TAE relative to TACE has 
been published (14), a recent prospective trial from 2009 
comparing DEB-TACE with TAE showed longer time to 
progression (TTP) and a greater percentage of individuals 
with complete response in the DEB-TACE group (17). 
More recently, a study was published demonstrating no 
difference in tumor response, progression free survival (PFS) 
or overall survival (OS) when comparing bland embolization 
with DEB embolization (18). As such, TAE and TACE 
may be regarded as relatively equal in their management of 
intermediate stage HCC, with definitive studies unlikely to 
be completed. Major complications of TAE are similar to 
TACE therapy (discussed below) and include liver failure, 
vascular injury, sepsis, non-target embolization, abscess/
biloma formation, and bleeding secondary to arterial access.
TACE
As the name suggests, chemoembolization employs a 
dual mechanism of action that results in a synergistic 
tumoricidal effect. The embolic agent induces ischemia 
and local hypoxia within the treated tissue. The intra-
arterial infusion of the chemotherapy agent delivers higher 
drug concentrations to the tumor than would otherwise 
be tolerated by the patient via a systemic route (21). 
The hypoxia induces secretion of vascular endothelial 
growth factor (VEGF), which results in increased vessel 
permeability (22). Leaking vessels in combination with 
hypoxia induce cell membrane dysfunction and stasis 
of blood flow leads to higher intracellular deposition 
of the chemotherapy agent and greater intra-hepatic 
retention. These changes result in less of the administered 
chemotherapy agent making it into the systemic circulation 
thus decreasing side effects and toxicity (8).
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Patient selection 
cTACE and DEB-TACE may have a select role as a second 
line treatment in early stage A patients who have recurrence 
after failing an above mentioned first line therapy. For 
intermediate stage B patients, those with multinodular 
HCC, a performance status of 0 and preserved liver function 
(Child-Pugh A), cTACE and DEB-TACE are considered first 
line therapies (21) with a 1A recommendation supporting their 
utilization (23). Select patients with elevated liver function, 
mildly impaired performance statuses with or without 
vascular invasion can be treated; however, the incidence 
of complications including liver failure increase in these 
populations. cTACE and DEB-TACE are contraindicated in 
patients with advanced cirrhosis (Child-Pugh C), performance 
status >2, significant extrahepatic tumor burden and patient’s 
with medically refractory hepatic encephalopathy. Relative 
contraindications include tumor within the main portal vein, 
biliary obstruction, total bilirubin >4, serum creatinine >2, and 
significant arteriovenous tumor shunting.
Technique
Overall technical performance of TACE is similar to TAE 
in practice in which a catheter and microcatheter system are 
negotiated into the hepatic arterial tree or accessory branches 
which feed the tumor. The goal of catheter placement during 
treatment is to achieve complete territorial coverage of the 
tumor vascularity sparing as much normal parenchyma as 
possible for delivery of chemotherapeutic embolization 
beads. Additionally, some institutions are performing TACE 
in conjunction with ablation as curative therapy (24), with 
one study demonstrating improved outcomes in single large 
HCCs (>3 cm) when compared to DEB-TACE alone (25).
cTACE
In cTACE, lipiodol (a poppy seed oil derivative) is 
utilized as the carrying embolic agent used to deliver the 
desired chemotherapy drug to the intended target. The 
most commonly used chemotherapy agents are cisplatin, 
doxorubicin, epirubicin and mitomycin C (26). The 
plethora of options available for concocting chemoembolic 
mixtures has resulted in significant variation in treatment 
protocols from center to center, making standardization of 
cTACE difficult. The formulated lipiodol chemotherapy 
solution is then administered through the catheter within 
the selected hepatic arterial distribution supplying the HCC 
lesion(s). Upon completion of the chemoembolic infusion 
and without change in catheter position, bland particles 
may be injected further decreasing arterial blood flow in the 
treated section of liver. That additional step is thought to 
improve the chemotherapy dwell time, hereby increasing 
tumor intracellular uptake and decreasing washout into the 
systemic circulation.
DEB-TACE
DEB-TACE represents the second iteration of cTACE 
where the liquid carrier embolic agent, lipiodol, has 
been replaced with microspheres ranging in size from 
approximately 45–300 μm with some institutions opting 
for larger particles. These microspheres are impregnated 
with a chemotherapy agent, most often with doxorubicin 
in the United States (27). As with all catheter directed 
local regional therapies, a catheter is positioned within the 
desired hepatic artery arterial distribution supplying the 
HCC lesion(s) through which the drug eluding beads are 
infused. The goal is to achieve near stasis of blood flow 
within the treated hepatic artery distribution at the end of 
infusion (28). Relative to cTACE, there is data to suggest 
DEB-TACE may result in longer tissue dwell times by the 
chemotherapy agent, ultimately increasing exposure of the 
targeted HCC lesion (29,30).
Outcomes
Response of HCC to chemoembolization is assessed on 
follow up imaging and is most often graded using the 
modified Response Evaluation Criteria in Solid Tumors 
(mRECIST) (31). Modified RECIST is preferred over 
RECIST 1.1 in evaluating response to treatment for 
liver lesions because RECIST assesses response to 
chemotherapeutic agents with changes in tumor size as the 
only contributing criteria it may be misleading when applied 
to targeted therapies (e.g., sorafenib) or interventional 
therapies. Due to mRECIST assessing for arterial phase 
enhancement it is more suited in assessing patients who 
have received targeted or interventional therapies. It is not 
entirely uncommon to demonstrate incomplete response 
or no response to therapy on follow up imaging after 
initial treatment of the HCC lesions; however, it has been 
demonstrated that failure to achieve adequate response 
after an initial round of chemoembolization is not an 
accurate predictor of poor tumor response to subsequent 
chemoembolization (32).
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TACE induced acute liver failure as defined by an 
increase in Child-Pugh score ≥2, elevation of total serum 
bilirubin by ≥2 mg/dL, or new hepatic encephalopathy or 
ascites occurring within 2 weeks of therapy is reported at 
a rate between 2% to 20% (33-35). Mild post procedure 
elevation of liver function tests is expected given the 
ischemic insult that occurs to normal liver parenchyma 
supplied by the same hepatic artery distribution as the 
targeted tumor. Major complications (vascular injury, sepsis, 
non-target embolization, abscess/biloma formation, biliary 
stricture or variceal bleeding) related to TACE occur in 
approximately 5% of cases with a 1% risk of death (33,36).
As seen in TAE, post embolization syndrome (abdominal 
pain, nausea, vomiting, ileus, fatigue and/or fever) is the 
most commonly reported adverse event associated with 
chemoembolization of HCC. It is experienced to some 
degree in up to 90% of cases (37) with the majority of 
symptoms markedly improving with 48–72 hours. 
Meta-analysis evaluating the effect of cTACE on OS 
when compared to conservative therapy demonstrated 
cTACE imparts a significant survival benefit to patients 
with an improvement in a 2-year survival ranging between 
20% to 60% (38) and improve median survival from 16 to 
20 months (39). DEB-TACE has also been demonstrated 
to have similar significant survival benefits, however recent 
head to head comparison of cTACE to DEB-TACE has 
failed to demonstrate a superior therapy when OS is the 
endpoint. The PRECISION V study did demonstrate a 
superior safety profile with DEB-TACE with significant 
reduction in the observed doxorubicin related side effects 
and serious liver toxicity when compared to cTACE (8). 
Patients treated with DEB-TACE required a significantly 
lower number of treatments which enhance the safety 
profile and lead to cost savings (40).
TARE with Yttrium-90 (Y90)
TARE (41) relies on the intraarterial delivery of radioactive 
spheres to the vascular beds of tumor. Y90 is a pure beta 
emitter with a half-life of 2.67 days and tissue penetration 
of up to approximately 11 mm with a mean of 2.5 mm. It is 
loaded on the surface of resin microspheres (SIR-Spheres, 
Sirtex Medical, Australia) or intrinsic to the glass matrix of 
microspheres (TheraSphere, Nordion, Canada), which range 
in size between 20–30 μm (Therasphere) and 20–60 μm 
(SIR-Spheres). The dominant antitumor effect of Y90 is 
induced by radiation as opposed to drug and ischemic effects 
as observed with TACE (42).
Patient selection
TARE using Y90 is a recognized treatment option with 
a palliative role in the treatment of unresectable HCC 
(43,44). Although BCLC guidelines suggest transarterial 
chemoembolization (TACE) is the standard of care for 
intermediate stage (BCLC B) disease, there is growing 
evidence for the role of Y90 in the treatment of these 
patients as well as those with either early (BCLC A) or 
advanced stage (BCLC C) disease (45,46). Importantly, 
Y90 has been shown to be safe in those patients with 
portal vein thrombosis (PVT) due to the reliance on 
delivery of radiation over blockade of vascularity as with 
TAE and TACE (47). Patients with Child-Pugh A (with/
without PVT) or Child-Pugh B (without PVT) disease 
staging are most likely to benefit from Y90 (44). Typical 
inclusion criteria for treatment of liver disease with Y90 
include total bilirubin <2.0 mg/dL with ECOG score 
0–2. Relative contraindications include renal failure and 
untreated portosystemic varices at risk of bleeding. Absolute 
contraindications include decompensated cirrhosis, tumor 
burden >75% of liver parenchyma, and uncorrectable 
shunts to either the lungs or gastrointestinal tract (45).
Technical considerations
Y90 is an intra-arterial radiation therapy that allows for 
much higher doses of radiation to be delivered to the 
diseased liver when compared to external beam radiation, 
which is limited by the radiosensitivity of normal liver 
parenchyma (48). Delivery of Y90 via the hepatic artery 
allows for preferential delivery of radiation to the tumors 
while minimizing impact on normal parenchyma due to the 
hypervascular nature of HCC. 
Y90 radioembolization is typically performed in a two-
stage manner. The first stage of the procedure involves 
an outpatient planning angiogram performed 1–2 weeks 
prior to treatment. Planning angiography provides the 
opportunity for vascular mapping, embolization of variant 
vascularity to ensure safe treatment, as well as evaluation 
of tumor shunting which would result in inadvertent 
radioactivity delivery to the lungs. In order to evaluate 
tumor shunting, technetium-99 m labeled macroaggregated 
albumin (MAA) is injected into the desired hepatic lobar 
or segmental artery followed by planar/SPECT gamma 
imaging to determine the fraction of shunting from the liver 
to the lungs (41).
The treatment phase, again performed on an outpatient 
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basis, involves delivery of Y90 in a lobar, segmental or 
sub-segmental fashion. Whole-liver therapy is generally 
avoided due to the increased risk of liver failure. Antibiotic, 
anti-emetic, and pain control medications are usually 
unnecessary following radioembolization. Responses to 
therapy may take up to 3–6 months on imaging (49) and 
therefore, typical clinic follow up is performed at 3 months 
intervals following treatment at which time biochemical and 
imaging follow up is obtained (44). One study demonstrated 
diffusion weighted imaging (9,50) at 1 month preceded 
anatomic size changes at 3 months post Y90 (43).
In addition to traditional Y90 administration in a staged 
lobar fashion, more novel treatment concepts are actively 
being investigated and include radiation “segmentectomy” and 
“lobectomy” as well as downstaging to liver transplantation (45).
Outcomes
Response rate, OS, and TTP following Y90 radioembolization 
vary depending on a number of factors, most importantly 
baseline patient stage (BCLC, UNOS, Child-Pugh). Sangro 
et al. demonstrated Median OS following radioembolization 
to be 24.4 months (BCLC A), 16.9 months (BCLC B), and 
10.0 months (BCLC C). The most significant prognostic 
factors for survival upon multivariate analysis included 
ECOG status, tumor burden (>5 nodules), an INR >1.2 and 
extrahepatic disease (51). TTP was longer for patients with 
Child-Pugh A and B without PVT, 15.5 and 13 months, 
respectively while patients with PVT demonstrated 5.6 and 
5.9 months, respectively. Median OS in patients without PVT 
has been demonstrated to be 17.3 (45) and 18.4 (51) months 
in Child-Pugh A and 13.5 months (45) in Child-Pugh B 
patients. Hilgard et al. demonstrated an overall TTP of 10.0 
with 8.0 and 11.8 months in patients with and without PVT 
respectively. Median OS of 16.4 months in patients without 
PVT while portal vein involvement dropped median OS to 
10.0 months (11).
The most common clinical toxicities include fatigue 
(57%), pain (23%), and nausea/vomiting (20%). Additionally, 
radioembolization-induced liver disease (REILD) 
is a syndrome that may appear 4–8 weeks following 
radioembolization manifesting as jaundice, ascites, and 
an increase in gamma-glutamyl transpeptidase/alkaline 
phosphatase in non-cirrhotic patients(45,52).
Although no survival benefit over TACE has yet to be 
demonstrated, radioembolization has been shown to provide 
secondary benefits over TACE including decreased toxicity (44) 
and improved quality-of-life regarding diarrhea, fever, 
chills adverse effects and anorexia (53). Furthermore, 
radioembolization can be performed on an outpatient basis. 
Given these factors Y90 is gaining acceptance as a treatment 
for late BCLC B (intermediate stage) and early BCLC C 
(advanced stage) disease(51,54).
Systemic therapy for advanced hepatocellular 
cancer
Selection of patients for systemic therapy
Patients meeting the definition of BCLC stage C are 
considered most optimal for systemic therapy. Within this 
group, however, lies a large range of clinical variables. As 
such, choices between locoregional and systemic therapy 
can be difficult (such as in a patient with a relatively large 
tumor who also has tumor-associated main or main branch 
PVT. There is little argument that this modality is a 
reasonable choice for patients with extrahepatic metastatic 
disease, or those whose tumors have progressed after one or 
more locoregional treatments. 
Early attempts at management focused on traditional 
cytotoxic chemotherapy, particularly doxorubicin (47). 
However, HCC has long been recognized as chemoresistant, 
with very low radiographic response rates to chemotherapy in 
modern trials (55,56). Thus to date, no single chemotherapy 
agent or combination of agents has led to a significant 
increase in OS (57,58). This has led research away from 
chemotherapy to targeted molecular antagonists of 
pathways thought to be critical to the pathogenesis of this 
disease. A milestone along that road has been the approval 
of sorafenib for the management of advanced HCC.
First line treatment
Similar to many other solid tumors, angiogenesis is important 
for the maintenance and growth of HCC. Sorafenib is a 
small molecule inhibitor of signaling pathways implicated 
in angiogenesis. Although initially characterized as a Raf-1 
and B-RAF inhibitor, it also abrogates phosphorylation 
and activation of tyrosine kinase domains of the vascular 
endothelial growth factor receptor (VEGFR), platelet 
derived growth factor (PDGFR), c-kit and flt1 (59). It was 
approved for the management of advanced HCC following 
improvement in OS reported by the SHARP trial (6). In this 
trial, 602 patients were randomized to sorafenib 400 mg 
twice daily or placebo. Eighty-two percent of the 
patients had advanced disease based on the Barcelona 
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Clinic Liver Cancer (BCLC) staging and 92% had an 
ECOG performance status of 1 and below. Only 5% of 
patients in the sorafenib arm had child pugh class B liver 
dysfunction with the rest falling into CP class A category 
with relatively well-preserved liver function. Median 
OS was 10.7 months with sorafenib and 7.9 months 
with placebo (HR: 0.69, 95% CI: 0.55–0.87) with an 
11% improvement in survival at 1 year (44% vs. 33% 
in the placebo arm). This result was complemented 
by similar findings of improved OS in the Asia-Pacific 
region (60). Cheng and colleagues reported an OS benefit 
improvement of about 2 months with sorafenib over 
placebo (6.5 vs. 4.2 months, HR: 0.68, 95% CI: 0.5–0.97). 
This study enrolled 271 patients and assigned them in a 2:1 
ratio to sorafenib and placebo. The difference in survival 
between the two studies has been attributed to the higher 
prevalence of patients with more advanced disease in the 
Asia-Pacific trial, with 95% of patients in this trial having 
Stage C BCLC HCC, compared to 82% in the SHARP 
trial. Also, 68% (vs. 53%) of patients had extra-hepatic 
spread of HCC. This is worth mentioning because extra 
hepatic spread was one of the sub-groups analyzed in the 
SHARP trial where sorafenib did not conclusively show a 
benefit. More importantly, the preponderance of hepatitis B 
virus (HBV) related disease in Asia-Pacific has been argued 
to be a reason for the relatively low survival rates as HBV 
related HCC has a more aggressive course with worse 
prognosis than hepatitis C virus (HCV) related disease 
which is prevalent in Western Europe and the United 
States. In keeping with this, in a sub-group analysis of the 
SHARP trial the small number of patients with HBV had 
shorter OS numbers compared to those with HCV related 
HCC (61).
Despite the relatively modest benefit conferred by sorafenib 
(and the attendant hope that other agents could reproduce 
or improve upon this success), there has been little progress 
with targeted therapy in almost a decade of subsequent drug 
development. A single arm phase II trial of bevacizumab, the 
prototypical angiogenesis inhibiting monoclonal antibody 
directed at VEGF appeared to show a strong signal for further 
development, with a median PFS of 6.9 months and an OS of 
12.4 months among 46 patients (62). Despite this, there has 
been no phase III trial to confirm this finding, with the field 
shifting towards combining bevacizumab with other agents 
similar to other malignancies (63). 
Brivanib is a dual kinase domain inhibitor of VEGFR and 
fibroblast growth factor receptor (FGFR). In addition to its 
proliferative effects, FGF may play a role in tumor invasion 
(64,65) and in overcoming resistance to VEGFR targeted 
therapy (66). The BRISK-FL study was a phase III non-
inferiority head to head study of brivanib and sorafenib in the 
first line setting (67). Despite similar median OS numbers 
of 9.9 months for sorafenib and 9.5 months for brivanib 
(HR: 1.06, 95% CI: 0.93–1.22), the study failed to meet the 
pre-specified upper limit hazard ratio for non-inferiority of 
HR less than or equal to 1.08. Brivanib was also less tolerable 
than sorafenib with the rate of drug cessation secondary to 
adverse events at 44% with brivanib and 33% with sorafenib. 
Sunitinib another multikinase inhibitor with similar targets 
to sorafenib, but with a stronger affinity for the VEGFR 
fared worse compared with sorafenib (68). Not only was OS 
shorter (7.9 vs. 10.2 months, HR: 1.2), it was significantly 
more toxic, with Grade 5 treatment related adverse events 
reported in 17 patients compared to 2 in the sorafenib arm. 
Similarly, linifanib did not show a benefit over sorafenib (69).
A common motif in the above investigations is that the 
studies have been based on agents that affect signaling of key 
angiogenesis receptor pathways. In line with the American 
Association for the Study of Liver Disease (AASLD) 
recommendations (70), investigators in the SEARCH trial (71), 
went in a different direction by attempting to antagonize 
a separate receptor pathway in addition to angiogenesis 
blockade. They compared the addition of erlotinib, an 
epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor (72) and sorafenib to sorafenib only. Despite the 
compelling rationale, the combination failed to scale the 
bar. There was a significant difference in disease control 
rates (DCR) in both arms, with the combination arm faring 
worse (43.9% vs. 52.5% P=0.021). Median OS was similar 
in both arms at 9.5 months with combination compared to 
8.5 months with sorafenib only (HR: 0.93, 95% CI: 
0.781–1.106). Other agents tried in the first line setting have 
been similarly underwhelming as noted in Table 1. 
So why have all these agents performed so poorly? A 
number of reasons have been put forward, chief among 
which are the clinical and molecular heterogeneity of HCC. 
As mentioned previously, patients with HBV related HCC 
have a more aggressive phenotype with worse prognosis 
than patients with HCV related disease. Importantly, the 
molecular pathogenesis of HCC is still being worked out. 
Similar to other solid tumors, there appears to be many 
more passenger mutations than driver mutations in human 
HCCs, and in instances where targeted therapies have been 
most successful, they have targeted critical driver mutations. 
A few driver gene mutations have been defined in HCC but 
the dominant driver remains unclear (77,78). Presumably, 
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staving off only one of these drivers would be insufficient to 
significantly check disease progression.
Sorafenib-refractory setting
In spite of a relatively large number of phase III trial 
“attempts”, no drug has been approved in the second line 
setting for advanced HCC. As in studies in the first line 
setting, agents targeted against angiogenic kinases have 
played a lead role in the sorafenib-refractory setting. Two 
large, phase III randomized studies, EVOLVE-1 and 
BRISK-PS failed to show benefit of targeted treatment in 
this setting. In the EVOLVE-1 trial (75), everolimus, an 
inhibitor of the mammalian target of rapamycin (mTOR) 
pathway (79) delivered an OS of 7.6 months compared to 
7.3 months for placebo (HR: 1.11, 95% CI: 0.91–1.36). 
The authors noted that the time to deterioration in physical 
functioning was shorter with everolimus. Despite better 
overall numbers—superior overall response rates (ORR) of 
10% vs. 2% (OR: 5.4, P=0.003) and DCR of 61% vs. 40% 
(OR: 2.38, P=0.001)—in the BRISK-PS (74) study, brivanib 
also ultimately failed to show a significant OS benefit 
compared to placebo [9.4 vs. 8.2 months (HR: 0.85, 95% CI: 
0.69–1.15)]. The story was similar with Ramucirumab (76). 
Curiously, in these second line studies, survival in the 
placebo arms were similar to the survival in the placebo 
arm of the SHARP trial of Sorafenib in the 1st line setting 
suggesting that patients with well-preserved liver function 
and/or less aggressive cancers were enrolled in these trials. 
The mRECIST (31) criteria for assessing response to 
therapy was published after the SHARP trial to account for 
the radiologic “pseudo-progression” secondary to tumor 
necrosis and bleeding which may be construed as treatment 
failure despite continued clinical benefit from sorafenib. 
Some patients with radiologic progression on sorafenib 
despite clinical stability may have been enrolled into these 
studies, as modified RECIST has not been universally 
adopted.
On a more positive note, recently, the results of 
the phase III RESORCE trial of regorafenib, another 
multikinase inhibitor, targeting the VEGFR among others 
was recently published. The authors reported an OS 
advantage over placebo (OS: 10.6 vs. 7.8 months, HR: 0.63, 
95% CI: 0.50–0.79) (73) and this finding is likely to change 
the management landscape of sorafenib refractory HCC. 
Interesting findings have also been reported in a phase II 
trial of tivantinib a c-MET inhibitor. Although there was no 
clinically meaningful difference in the primary end point of 
TTP of 1.6 vs. 1.4 months (HR: 0.64, 90% CI: 0.43–0.94), 
and other end points including PFS and OS, between 
tivantinib and placebo, pre-planned subgroup analysis 
revealed a doubling of TTP with tivantinib in a c-MET high 
group compared to placebo (2.7 vs. 1.4 months, HR: 0.43, 
95% CI: 0.19–0.97) (80). This has prompted a phase III trial 
Table 1 Completed phase III clinical trials of targeted therapy in advanced hepatocellular cancer
Author, year Treatment (setting) Molecular targets Number
Median TTP 
(months)
Median OS 
(months)
Llovet, 2008 (6) Sorafenib vs. placebo (1st line) VEGFR, PDGR, RAF, c-kit 602 5.5 vs. 2.8 10.9 vs. 6.5
Cheng, 2009 (60) Sorafenib vs. placebo (1st line) VEGFR, PDGR, RAF, c-kit 271 2.8 vs. 1.4 6.5 vs. 4.2
Cheng, 2013 (68) Sorafenib vs. sunitinib (1st line) VEGFR, PDGR, RAF, c-kit, RET 1,074 4 vs. 3.8 10.2 vs. 7.8
Johnson, 2013 (67) Sorafenib vs. brivanib (1st line) VEGFR, FGFR 1,155 4.2 vs. 4.1 9.8 vs. 9.9
Cainap, 2015 (69) Sorafenib vs. linifanib (1st line) VEGFR, PDGFR 1,035 4 vs. 5.4 9.8 vs. 9.1
Zhu, 2015 (71) Sorafenib vs. sorafenib and erlotinib 
(1st line)
EGFR 720 4 vs. 3.2 8.5 vs. 9.5
Bruix, 2016 (73) Regorafenib vs. placebo (2nd line) VEGFR, PDGFR, Tie-2, B-Raf, RET, c-kit 573 3.2 vs. 1.5 10.6 vs. 7.8
Llovet, 2013 (74) Brivanib vs. placebo (2nd line) VEGFR, FGFR 395 4.2 vs. 2.7 9.4 vs. 8.2
Zhu, 2014 (75) Everolimus vs. placebo (2nd line) mTOR pathway 546 3 vs. 2.6 7.6 vs. 7.3
Zhu, 2015 (76) Ramucirumab vs. placebo (2nd line) VEGFR2 565 3.5 vs. 2.5 9.2 vs. 7.6
VEGFR, vascular endothelial growth factor receptor; PDGR, platelet derived growth factor receptor; RAF, rapidly accelerated fibrosarcoma; 
RET, rearranged during transfection,; FGFR, fibroblast growth factor receptor; EGFR, epidermal growth factor receptor; mTOR, mammalian 
target of rapamycin.
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of tivantinib compared to placebo in c-MET high HCC.
Loco-regional therapy and sorafenib
TACE is the most commonly employed option for loco-
regional therapy, with multiple guidelines endorsing this 
approach in intermediate stage HCC (13,81). Despite the 
significant improvement in TTP and OS with TACE, 
BCLC stage B HCC is largely incurable. Cytotoxicity and 
disease control are engendered in the short term, but TACE 
ultimately promotes angiogenesis on account of the hypoxia 
induced by embolization. This leads to up regulation of 
HIF-1alpha, and eventual production of angiogenic factors 
particularly VEGF (82). The rationale for combining 
sorafenib with catheter-based treatment in HCC is to 
counteract this paradoxical angiogenic effect with the hope 
of extending clinical benefit derived from TACE. This has 
however, not been borne out in clinical trials. 
Among Japanese and Korean patients with intermediate 
stage HCC who had at least 25% tumor shrinkage with 
TACE, subsequent administration of sorafenib did not 
provide additional benefit in terms of OS or TTP (83). 
Others have focused on concurrent administration of 
sorafenib and TACE with multiple studies confirming 
the safety of this approach (84-86). These studies also 
suggested interesting efficacy numbers in terms of OS and 
TTP although they were mostly single arm studies and not 
powered to determine such an effect. The SPACE trial is a 
phase II trial that randomized 307 patients to TACE-DEB 
with sorafenib and TACE-DEB with placebo (87). There 
was no difference in the primary end point of TTP in both 
arms at 169 vs. 166 days in the sorafenib arm compared to 
placebo (HR: 0.797; 95% CI: 0.588–1.080, P=0.072). A 
major problem with this study was that in close to a third 
of patients randomized, initially described target lesions 
were not confirmed on central radiological review. More 
importantly, a similar fraction received only one round of 
TACE on account of adverse events, which may very well 
have been reversible allowing the patients to undergo and 
possibly benefit from further therapy. It remains unclear 
why the combination of TACE and sorafenib has not 
been as beneficial as expected, but some experts speculate 
that patients with more advanced disease are more likely 
to benefit from this combined approach than those with 
intermediate stage disease (88). The GIDEON study 
suggests this (89), but this is registry data with only a small 
number of reports of concurrent TACE and sorafenib. At 
this time, there is no high quality evidence to suggest that 
adding sorafenib to a catheter- based treatment modality is 
beneficial.
Novel options and future perspectives
Although it appears that therapy directed at angiogenesis and 
VEGFR signaling may have hit a ceiling, it is encouraging 
that drug development for advanced HCC continues 
to explore new avenues. Immunotherapy with immune 
checkpoint blockade is undoubtedly one of the most exciting 
areas in cancer therapeutics in the last few years, with 
significant clinical activity reported with CTLA-4 and PD-1 
blocking agents, particularly in melanoma (90) and non-small 
cell lung cancer (NSCLC) (91,92). This has significantly 
and positively impacted outcomes in these diseases. In 
line with results from other solid tumors, investigators are 
reporting promising activity in HCC also. A phase II trial of 
nivolumab, an anti PD1 monoclonal antibody, was reported 
at the recent American Society of Clinical Oncology (ASCO) 
annual meeting (93). Investigators reported that nivolumab 
was tolerable, with grade 3–4 adverse events reported in 
20% of 51 patients, most commonly elevations in liver 
enzymes. Median OS in this small study was 15.1 months 
(95% CI: 9.6–28.6 months). Importantly close to half of 
the patients were still alive after 18 months. We note that 
enrolled patients had relatively well-preserved liver function 
with CPS grade A. A phase III trial comparing nivolumab 
to sorafenib is already recruiting participants comparing 
nivolumab to sorafenib in the first line setting (94). A phase 
III trial of pembrolizumab, another PD-1 inhibitor is also 
recruiting patients who have advanced on sorafenib (95) and 
other immunotherapy options including cancer vaccines 
and immune stimulators are in various stages of drug 
development.
Discussion and summary
HCC is well recognized as an aggressive tumor and for 
those patients who are not candidates for curative therapy 
transarterial and systemic therapies offer a good alternative 
in slowing tumor progression. With the wide variety of 
treatment modalities, a multidisciplinary approach to 
therapeutic considerations is recommended. While other 
modalities offer curative therapies in limited disease, the 
majority of cases presents beyond early stage disease and 
receive catheter directed therapy for downstaging of tumor 
burden or as definitive therapy. When deciding between 
the available transarterial therapies it is important to 
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realize that no clear evidence suggesting one therapy over 
another exists however many factors must be considered 
including institutional availability, physician skill-set and 
training, inpatient versus outpatient therapy, as well as cost. 
When it comes to transarterial therapies, one important 
consideration that applies to all embolic based therapies, 
is that blockade of hepatic arteries at a proximal or distal 
level can lead to collateral vessel formation (96), which may 
limit the ability to repeat embolization by conventional 
hepatic vasculature. Formation of collateral vasculature may 
preclude effective treatment with radioembolization if extra-
hepatic supply is recruited. Because of this phenomenon 
treatment with TAE or TACE can preclude effective 
treatment with Y90. Because much of our knowledge 
about transcatheter therapies for liver malignancy involves 
retrospective studies, little data exists offering head to 
head comparison for available treatment options and 
more prospective studies and comparative studies between 
treatments is needed.
In terms of systemic therapies, it is likely that in patients 
with preserved liver function, combination therapy with 
agents targeting different driver signaling pathways (and the 
tumor microenvironment) may lead to further improvement 
in outcomes in this disease. Combined locoregional and 
systemic therapies, particularly the immunotherapies, are 
also early in study and results very much anticipated. To 
achieve a goal of substantial improvement, however, it is 
vital that we continue to work out the molecular events that 
underpin the pathogenesis of HCC.
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